Inhibitor Therapeutics INTI
OTC INTI
$0.11 +0.00 (+0.00%)
At close: Oct 20, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Preferred Stock Liabilities (2018)

Updated

Inhibitor Therapeutics (INTI) reported Preferred Stock Liabilities of $7.92 million for Q3 2018, up 67.8% from the prior quarter.

Analysis

Inhibitor Therapeutics (INTI) Preferred Stock Liabilities (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Inhibitor Therapeutics 19.12 Mn 11.93 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 7.92 Mn
Jun 30, 2018 4.72 Mn
API Access

Inhibitor Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=INTI&period=max&api_key=YOUR_API_KEY